Anti-BCMA-Anti-CD19-Anti-CD3 Trispecific Molecule

Only %1 left

Catalog #

100761

As low as $390 *

Cat # Size Price*

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

The Anti-BCMA-Anti-CD19-Anti-CD3 Trispecific Molecule is engineered to bind to three different targets simultaneously: 1) BCMA, a B cell antigen that is highly expressed by mature B cells and malignant myeloma cells, 2) CD19, a B-cell marker that is a target for many leukemias and lymphomas, and 3) CD3, a T cell receptor activation signal that leads to cytokine secretion. The multi-functionality of this trispecific molecule allows it to bind to BCMA and CD19 on the tumor cell and CD3 on T cells simultaneously, thus bringing T lymphocytes closer to the cancer cells. The binding event targets the tumor while providing co-stimulatory signals that promote T cell expansion and cytotoxicity against BCMA+ and CD19+ cancer cells.

●

Synonyms

Cluster of Differentiation 19 antibody, B-Lymphocyte Surface Antigen B4 antibody, CVID3, B-cell maturation antigen, TNFRSF17

●

Product Data Gallery

4-20% SDS-PAGE Coomassie staining

Titration of BCMA Biotin (BPS Bioscience #79467-1) or control non-specific biotinylated protein binding to anti-BCMA-anti-CD19-antiCD3-His coated on an ELISA plate, followed by streptavidin-HRP and chemiluminescent detection

Binding of CD19-Biotin (BPS Bioscience #79475) or control non-specific biotinylated protein to anti-BCMA-anti-CD19-anti-CD3-His coated on an ELISA plate, followed by streptavidin-HRP and chemiluminescent detection.

Activation of NFAT Reporter Jurkat cells by Anti-BCMA-Anti-CD19-AntiCD3 Trispecific Molecule in the presence of BCMA-CHO cells or CHO cells.

Activation of NFAT Reporter Jurkat cells by Anti-BCMA-Anti-CD19-AntiCD3 Trispecific Molecule in the presence of CD19-CHO cells or CHO cells.

Product Info

Storage and Usage

Citations

Species

Human

Host Species/Expression System

HEK293

Purity

88%

Supplied As

Aqueous buffer solution.

Purification

His-tag affinity purification from HEK293 cells

Formulation

8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol

82 kDa +glycans

Amino Acids

1-763

UniProt #

BCMA: Q02223; CD19: P15391

Tag(s)

N-terminal His-tag

Background

B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein encoded by the TNFRSF17 gene. TNFRSF17 is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. Upregulation of BCMA also correlates with disease burden and prognosis in multiple myeloma.

B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be used as a target for leukemia immunotherapies.

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Anti-BCMA-Anti-CD19-Anti-CD3 Trispecific Molecule

PRODUCTS

SERVICES

RESOURCES

COMPANY